Rheumatoid Arthritis

TNF-alpha Inhibitor Enters Phase I Human Clinical Trials

Published in Gene Therapy Weekly, November 9th, 2000

Isis Pharmaceuticals (ISIP), Carlsbad, California, announced it has initiated Phase I clinical studies of ISIS 104838, an antisense drug to treat inflammatory and autoimmune diseases such as rheumatoid arthritis (RA) and Crohn's disease.

ISIS 104838, an inhibitor of TNF-alpha, has enhanced properties as it employs Isis' proprietary second-generation antisense chemistry, which is more potent than first generation chemistries. The clinical program for ISIS 104838 will investigate the safety and efficacy of the drug administered intravenously (IV) and subcutaneously.

Oral formulations of ISIS 104838 are being developed in parallel by OraSense Ltd., a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-11-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry